ISRCTN63987586
Completed
未知
A Phase II randomised controlled trial of an early tailored cognitive behavioural therapy based intervention for depression in those newly diagnosed with multiple sclerosis
Multiple Sclerosis Research Australia0 sites60 target enrollmentOctober 20, 2017
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Mild to moderate depression among individuals newly diagnosed with MS
- Sponsor
- Multiple Sclerosis Research Australia
- Enrollment
- 60
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
2020 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/31959224 protocol (added 22/01/2020)
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Mild to moderately depressed patients with MS
- •2\. Diagnosed with MS within the last 5 years and are considered newly diagnosed.
- •3\. Adult (i.e., 18\-65 years old)
Exclusion Criteria
- •1\. Gross cognitive impairment that would make participation in the 8 one hour sessions of Cognitive Behavioural Therapy distressing
- •2\. Unable to speak or read English
- •3\. Acute organic brain syndrome (e.g., delirium)
- •4\. Serious psychological disorder (e.g., psychosis)
- •5\. Assessed with the BDI\-II and the SCID\-5 as being severely depressed
- •6\. Already undertaking psychological treatment for depression/anxiety
- •7\. Taking antidepressants for less than two months
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 2
Radiotherapy combined with immunotherapy in metastatic non-small cell lung cancer patientsCancerAdvanced non-small cell lung cancer, stage IVMalignant neoplasm the lung, non-small cell lung cancerISRCTN49817477Maastricht University88
Completed
Not Applicable
Evaluation of Groups for Alcohol-misusing Short-term PrisonersISRCTN68904585Abertawe Bro Morgannwg University Health Board (UK)238
Completed
Phase 2
Trial of ursodeoxycholic acid for Parkinson’s diseaseISRCTN73371260Sheffield Teaching Hospitals NHS Foundation Trust30
Terminated
Phase 2
apatinib plus capecitabine versus continued trastuzumab plus capecitabine after local therapy in patients with ErbB2-positive metastatic breast cancer developing brain metastasis/esBreast cancer, developing brain metastasis/esCancerBreast cancerISRCTN58771616eeds Teaching Hospitals NHS Trust (UK)30
Completed
Not Applicable
Evaluation of a computer aid for assessing stomach symptomsISRCTN12595588niversity of Durham (UK)530